FDA To Review Pfizer’s Abrilada For Humira Interchangeability
Adalimumab Biosimilar Is Set For US Launch In July 2023
The US FDA is reviewing Pfizer’s Humira biosimilar, Abrilada, to assess whether the compound can be granted an interchangeability designation with the original drug.
